Vonoprazan is a potassium-competitive acid blocker used in the treatment of acid-related disorders and as an adjunct to Helicobacter pylori eradication. Vonoprazan is a potassium-competitive acid blocker (PCAB) that inhibits H+, K+-ATPase-mediated gastric acid secretion.
- Mechanism
- Curator reviewed · 2 references
Vonoprazan is a potassium-competitive acid blocker (PCAB) that inhibits the H+, K+-ATPase enzyme system in a potassium-competitive manner. Through this mechanism, vonoprazan suppresses basal and stimulated gastric acid secretion at the secretory surface of gastric parietal cells.
Although both classes of drugs inhibit the H+, K+-ATPase, the mechanism of action of PCABs differs from that of proton-pump inhibitors (PPIs). PPIs form a covalent disulphide bond with a cysteine residue on the H+, K+-ATPase, which leads to the inactivation of the enzyme, while PCABs interfere with the binding of K+ to the H+, K+-ATPase.
- Primary indication
- Vonoprazan is indicated for the following conditions: for healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. - to maintain healing of all grades of erosive esophagitis...Curator reviewed · 11 structured indications
- Formula / weight
- C17H16FN3O2S · 345.39 g/mol (avg)
- First approval
- United States, 2023
- Code names
- TAK-438
- Brand names
Resolves to
BFDBKMOZYNOTPK-UHFFFAOYSA-NSMILESCNCC1=CN(C(=C1)C1=CC=CC=C1F)S(=O)(=O)C1=CC=CN=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Vonoprazan, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account